HC Wainwright Reiterates “Buy” Rating for Disc Medicine (NASDAQ:IRON)

by · The Markets Daily

HC Wainwright reissued their buy rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a report issued on Tuesday morning,Benzinga reports. They currently have a $70.00 price objective on the stock.

Other analysts have also recently issued research reports about the stock. Raymond James raised shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and increased their price objective for the stock from $66.00 to $110.00 in a report on Monday, November 4th. Scotiabank began coverage on shares of Disc Medicine in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $62.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and issued a $75.00 price target (up from $60.00) on shares of Disc Medicine in a research note on Monday, November 4th. Wells Fargo & Company began coverage on shares of Disc Medicine in a research note on Thursday, August 22nd. They set an “overweight” rating and a $75.00 price objective on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $85.00 target price on shares of Disc Medicine in a research report on Tuesday, October 15th. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Disc Medicine currently has a consensus rating of “Buy” and a consensus target price of $80.20.

Check Out Our Latest Research Report on IRON

Disc Medicine Price Performance

Disc Medicine stock opened at $65.00 on Tuesday. The company has a market cap of $1.93 billion, a PE ratio of -17.71 and a beta of 0.60. Disc Medicine has a 12 month low of $25.60 and a 12 month high of $77.60. The company has a fifty day moving average price of $49.94 and a two-hundred day moving average price of $43.74.

Disc Medicine (NASDAQ:IRON – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($1.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.08. Equities research analysts anticipate that Disc Medicine will post -4.09 earnings per share for the current year.

Insider Buying and Selling

In other news, Director William Richard White sold 7,136 shares of the business’s stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $58.61, for a total transaction of $418,240.96. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In the last quarter, insiders have sold 7,538 shares of company stock valued at $437,875. 4.24% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the business. Jennison Associates LLC increased its holdings in Disc Medicine by 349.1% in the first quarter. Jennison Associates LLC now owns 193,240 shares of the company’s stock worth $12,031,000 after buying an additional 150,209 shares during the last quarter. Swiss National Bank boosted its holdings in Disc Medicine by 50.6% in the first quarter. Swiss National Bank now owns 23,800 shares of the company’s stock worth $1,482,000 after purchasing an additional 8,000 shares in the last quarter. ProShare Advisors LLC acquired a new position in Disc Medicine during the first quarter worth $211,000. Bleakley Financial Group LLC raised its holdings in Disc Medicine by 23.0% during the first quarter. Bleakley Financial Group LLC now owns 4,572 shares of the company’s stock valued at $285,000 after buying an additional 856 shares in the last quarter. Finally, Lord Abbett & CO. LLC acquired a new stake in shares of Disc Medicine in the first quarter worth about $7,429,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.

About Disc Medicine

(Get Free Report)

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.

Featured Articles